Mr. Culverwell has served as a director of Quoin Inc. since April 2021 and as a director of Quoin Ltd. since October 28, 2021. He is also currently serving as the Chief Executive Officer and Chairman of the Board of Directors of HOX Therapeutics. He serves as a director and Audit Committee Chairman of TC BioPharm (Holdings) plc (Nasdaq: TCBP) and he serves as a director, Audit Committee Chairman, and member of the Compensation Committee of SafeGuard Biosystems. In 2005, Mr. Culverwell founded Sudbrook Associates, which provided strategic advice and fundraising services for life science companies. Previously, Mr. Culverwell was Senior Vice President and Global Coordinator Healthcare Research at Merrill Lynch. He also served as Director of Healthcare Equity Research at ABN Amro Bank N.V., director and Audit Committee Chairman of Amryt Pharma PLC (Nasdaq: AMYT), and director and Audit Committee Chairman of Innocoll AG. He received an MSc with honors from the University of Aberdeen.
Rare diseases are only rare if you don’t live with one.®
Subscribe to Email Alerts
Sign up for alerts to stay up to date on Quoin Pharmaceuticals.
Latest News:
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate Self-Commercialization of QRX003 in Japan, if Approved Orphan Drug...
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome
If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as a treatment for Netherton Syndrome in 2H 2026 QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Quoin...